Randomized Trial of Ceftazidime-Avibactam vs Meropenem for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (REPROVE): Analyses per US FDA–Specified End Points

BACKGROUND: Hospital-acquired and ventilator-associated pneumonia (HAP/VAP; nosocomial pneumonia) due to Gram-negative pathogens are associated with significant morbidity and mortality; treatment options for multidrug-resistant infections are limited. The pivotal phase III REPROVE trial evaluated th...

Descripción completa

Detalles Bibliográficos
Autores principales: Torres, Antoni, Rank, Doug, Melnick, David, Rekeda, Ludmyla, Chen, Xiang, Riccobene, Todd, Critchley, Ian A, Lakkis, Hassan D, Taylor, Dianna, Talley, Angela K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Major Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6483139/
https://www.ncbi.nlm.nih.gov/pubmed/31041348
http://dx.doi.org/10.1093/ofid/ofz149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6483139/
https://www.ncbi.nlm.nih.gov/pubmed/31041348
http://dx.doi.org/10.1093/ofid/ofz149

Ejemplares similares